HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

Author(s):
Bartlett, J.M.S.; Ahmed, I.; Regan, M.M.; Sestak, I.; Mallon, E.A.; Dell'Orto, P.; Thurlimann, B.; Seynaeve, C.; Putter, H.; Velde, C.J.H. van de (0000-0003-0104-1800); Brookes, C.L.; Forbes, J.F.; Viale, G.; Cuzick, J.; Dowsett, M.; Rea, D.W.; Translational Aromatase Inhibitor
Published
2017
Publication type
Article / Letter to editor
Breast cancerHER2PredictionAromatase inhibitorMeta-analysis
Date issued
2017-07-31
Language
English
Is part of
European Journal of Cancer (2017), Vol. 79, p. 129-138
hdl
1887/116323
doi
10.1016/j.ejca.2017.03.033